Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H30F2N6O8S |
Molecular Weight | 648.635 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)N2C=C(N=N2)C3=CC=CC(F)=C3)S[C@]4([H])O[C@H](CO)[C@H](O)[C@@H]([C@H]4O)N5C=C(N=N5)C6=CC=CC(F)=C6
InChI
InChIKey=YGIDGBAHDZEYMT-MQFIMZJJSA-N
InChI=1S/C28H30F2N6O8S/c29-15-5-1-3-13(7-15)17-9-35(33-31-17)21-23(39)19(11-37)43-27(25(21)41)45-28-26(42)22(24(40)20(12-38)44-28)36-10-18(32-34-36)14-4-2-6-16(30)8-14/h1-10,19-28,37-42H,11-12H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1
TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3. TD139 is formulated for inhalation, which enables direct targeting the fibrotic tissue in the lungs, while minimizing systemic exposure. TD139 was initially developed by a team of scientists from Lund University, Sweden, and Edinburgh University, the UK. TD-139 is in phase I/II clinical trials for the treatment of idiopathic pulmonary fibrosis.
Approval Year
Sample Use Guides
TD139 is delivered to the lungs of IPF patients using the Plastiape inhaler device at the following 3 doses: 0.3mg, 3mg, and 10mg.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22095546
Primary alveolar epithelial cells from wild-type (WT) mice were plated and treated with transforming growth factor (TGF)-b1 in the presence or absence of 10 uM TD-139. TD-139 (10 uM) blocked TGF-b1–induced
b-catenin phosphorylation as judged by Western blot analysis.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
757320
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
60Y0GUO72B
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY | |||
|
DB12895
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY | |||
|
73774610
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY | |||
|
JK-29
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY | |||
|
C174126
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY | |||
|
12032
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY | |||
|
1450824-22-2
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY | |||
|
300000011291
Created by
admin on Sat Dec 16 08:30:07 UTC 2023 , Edited by admin on Sat Dec 16 08:30:07 UTC 2023
|
PRIMARY |
ACTIVE MOIETY